STATEN ISLAND, N.Y., March 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,745,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.40 per share (or per common stock equivalent in lieu thereof) in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered short-term warrants ...

TORONTO, March 7, 2025 /PRNewswire/ -- Recently, Visionary Holdings has achieved a significant breakthrough in the field of new energy vehicles by successfully securing an order for 12,000 new energy vehicles (Hong Kong taxi version). The attainment of this order not only showcases the company's remarkable strength in new energy vehicle manufacturing but also lays a solid foundation for its further expansion in the Hong Kong market. At the same time, Visionary Holdings has announced that it will simultaneously promote the establishment of a network of battery swap service stations in Hong Kong, aiming to provide efficient and convenient battery ...

A Former Health System CEO, Mr. Statuto Has Over 30 Years of Leadership Experience CHARLES TOWN, W.V., March 7, 2025 /PRNewswire/ -- American Public Education, Inc. (Nasdaq: APEI) today announced it has appointed Richard J. Statuto, an accomplished health system CEO, to its Board of Directors, effective March 6, 2025. The appointment brings the total number of APEI board members to nine.

VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to the World Health Organization (WHO), breast cancer cases are projected to rise by nearly 40% by 2050. Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Exelixis, Inc. (NASDAQ: EXEL), Cardiff Oncology, Inc. (NASDAQ: CRDF), ALX Oncology Holdings ...